|
|
|
|
|
Tenecteplase
drug data and news
Tenecteplase drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Tenecteplase | ||
| Brand Names/Synonyms | Tissue-type plasminogen activator precursor;tPA;t- PA;t-plasminogen activator;Alteplase;Reteplase; TNKase (Genentech Inc) | ||
| Indication | For treatment of myocardial infarction and lysis of intracoronary emboli | ||
| Sponsored links | Description | Tissue plasminogen activator (tPA). Tenecteplase is a 527 amino acid glycoprotein developed by introducing the following modifications to the complementary DNA (cDNA) for natural human tPA: a substitution of threonine 103 with asparagine, and a substitution of asparagine 117 with glutamine, both within the kringle 1 domain, and a tetra-alanine substitution at amino acids 296-299 in the protease domain. | |
| Pharmacology | Cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. This helps eliminate blood clots or arterial blockages that cause myocardial infarction. | ||
| Mechanism Of Action | TNKase cleaves the Arg/Val bond in plasminogen to form plasmin. This in turn leads to the degradation of blood clots. | ||
| Tenecteplase News (When available) |
| ||
| Dosage Forms | POWDER FOR SOLUTION | ||
| Drug_Category | Thrombolytic Agents | ||
| Absorption | Not Available | ||
| Interactions | Not Available | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | Human tissue plasminogen activator | ||
| Chemical Formula | C2561H3919N747O781S40 | ||
| Molecular Weight | 58951.2 | ||
| Smiles String | Not Available | ||
| Melting Point | 60 oC (Novokhatny, V.V. et al., J. Biol. Chem. 266:12994-123002 (1991)) | ||
| Water Solubility | Not Available | ||
| State | Transparent, slightly viscous, aqueous liquid | ||
| LogP/Hphobicity | -0.528 | ||
| Isoelectric Point | 7.61 | ||
| Biotransformation | Not Available | ||
| Half Life | 1.9 hours (mammalian reticulocytes, in vitro). >20 hours (yeast, in vivo). >10 hours (Escherichia coli, in vivo). | ||
| Protein Binding [%] | Not Available | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Tenecteplase.html http://www.rxlist.com/cgi/generic2/tenecteplase.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | BIOD00019 | ||
| CAS Registry Number | 105857-23-6 | ||
| KEGG Compound ID | Not Available | ||
| PubChem ID | Not Available | ||
| PharmGKB ID | PA451610 | ||
| SwissProt ID | TPA_HUMAN (P00750) | ||
| GenBank ID | L00153 | ||
| Drug ID Number [DIN] | 2244826 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |